Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Sex: Female

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 30

Sponsor: Weill Medical College of Cornell University

Summary

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.

Eligibility Criteria

Inclusion Criteria: * Biologically female * Age ≥ 18 * Obesity as defined by current BMI ≥ 30 kg/m² * Postmenopausal as defined by one or more of the following * Age ≥60 years * Age \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07257484). StuddyBuddy aggregates publicly available trial information.